In final draft guidance NICE recommended use of Xarelto at a dose of 2.5mg daily combined with aspirin, as an option for preventing atherothrombotic events in adults with coronary artery disease ...

The company maintained that it can “largely compensate” for the Xarelto declines, which this quarter added up to a 23.8% year-over-year dip to 802 million euros ($851 million), pharma group ...

Bayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving the way for a potential new indication for the anticoagulant.